tirzepatide fda approval date Eli Lilly's gained in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly Tirzepatide Weight Loss Approval: Clinical

Compare this to tirzepatide, which can produce 22.5% total body weight loss over 72 weeks

The effect of copper peptide (GHK-Cu) on the healing of ischemic wounds

The effects of gender, age and baseline CV risk on outcomes are important considerations for further study

Research published in Journal of Pharmacology & Pharmacotherapeutics explains that SSRIs desensitize 5-HT receptors over time

Perimenopause Weight Loss: A Guide to HRT and GLP-1 Medications Weight gain during perimenopause affects many women in their 40s and early 50s, with research showing an average gain of 1.1 pounds per year due to aging during this period of life

The key clinical message is that no safety signal for increased suicidality was observed